EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Entrada Therapeutics Inc (TRDA) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Entrada Therapeutics Inc $6.04, price $6.50, upside -7.1%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US29384C1080

ET Entrada Therapeutics Inc logo Thin data Sep 23, 2026

Entrada Therapeutics Inc

TRDA · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $6.04 · Fairly valued (−7%)
!Quality 22/100
!Weak Growth (revenue 3y +0.2 %/yr)
!negative free cash flow
!Trails peers (2/7)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 24 out of 100
Watch Entrada Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$35.00 $5.02 Fair Value $6.04 Oct 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

59‑month range $5.02 – $35.00 · fair‑value band $3.98 – $7.54 · the $6.50 price screens above the $6.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Entrada Therapeutics in your weekly email

Every Wednesday you see whether Entrada Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.

Show more

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Stock analysis

Entrada Therapeutics Inc (TRDA) currently trades at $6.50, while our model-based Fair Value estimate is $6.04, implying the stock looks roughly 7.6% fairly valued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $3.98 (bear) to $7.54 (bull), the price of $6.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Entrada Therapeutics Inc reported revenue of $25.4M in FY2025 versus $0 in FY2021. Reported net income was −$144M in FY2025.

Key figures

Market cap $274M · P/S ratio 56.1 · EPS (TTM) $−3.96 · Return on equity −54.1% · Return on assets (EBIT) −17.7% · Operating margin −5,007% · Revenue growth (YoY) −53.9% · Free cash flow −$130M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −7%, TRDA screens richer than that median.

Fair Value models

Bear $3.98 Fair Value $6.04 Bull $7.54
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $3.93 $5.27 $7.86 51
All 1 models by family
Asset-Based
NCAV (Graham) $3.93 $5.27 $7.86 51

Open the full fair value analysis →

Notify me when TRDA reaches fair value

Put TRDA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 22/100

Of which business quality 26 · Market factors (momentum, volatility) 40

Profitability 2
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 70
Balance sheet, leverage, solvency risk
Investment 51
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 36
Distance to the 52-week high (market factor)
Net Issuance 30
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−87.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−385.0% (2022) → −613.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch TRDA, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (84 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Entrada Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −7% · Above median
Profitability
Return on assets −29% · Below median
Growth and dividend
Revenue growth −54% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.90× · Cheaper than median
P/S (TTM) 58.57× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)24 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Entrada Therapeutics Inc · Fair Value
$6.04 −8%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Entrada Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/TRDA

Frequently asked questions

Is Entrada Therapeutics Inc (TRDA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $6.04 versus a price of $6.50, about −7% upside (fairly valued).
What is the fair value of TRDA?
Our model-based fair value for Entrada Therapeutics Inc is $6.04 (as of Sep 23, 2026), built from audited fundamentals. The current price: $6.50.
What is the quality score of TRDA?
Entrada Therapeutics Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Entrada Therapeutics Inc (TRDA)?
Our model-based price target is the fair value of $6.04 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $3.98, optimistic scenario $7.54. It is a calculation from audited fundamentals, not an analyst target.
What is the Entrada Therapeutics Inc stock forecast for 2026?
Our models put fair value at $6.04, about −7% upside versus a price of $6.50 (fairly valued). Cautious scenario $3.98, optimistic scenario $7.54. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Entrada Therapeutics Inc (TRDA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Entrada Therapeutics Inc it is $6.04 per share (as of Sep 23, 2026), against a price of $6.50. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Entrada Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, TRDA trades above its calculated fair value: price $6.50, fair value $6.04, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TRDA?
No. The price is what the market pays today ($6.50); the fair value is what the company's own numbers justify ($6.04). For Entrada Therapeutics Inc the two are $0.4600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Entrada Therapeutics Inc worth?
The market values Entrada Therapeutics Inc at about $274M (market capitalisation, as of Sep 23, 2026). Per share that is $6.50; our models calculate a fair value of $6.04 per share.
What do the bullish and bearish scenarios say about TRDA?
Our models span a range for Entrada Therapeutics Inc: cautious scenario $3.98, base $6.04, optimistic $7.54 per share (as of Sep 23, 2026, price $6.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Entrada Therapeutics Inc (TRDA)?
Balance-sheet figures for Entrada Therapeutics Inc (as of Sep 23, 2026): return on equity −54.1%. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is TRDA from its 52-week high?
Entrada Therapeutics Inc trades at $6.50, about 59% below its 52-week high of $16.03 and 28% above the low of $5.09 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $6.04 is for.
Which stocks are comparable to Entrada Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Entrada Therapeutics Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $6.50, calculated fair value $6.04 (−7%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TRDA calculated?
We run Entrada Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $6.04, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Entrada Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Entrada Therapeutics Inc (TRDA)?
The closing price on Sep 23, 2026 was $6.50. Our model-based fair value is $6.04, about −7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Entrada Therapeutics Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($3.98 to $7.54) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Entrada Therapeutics Inc

How large is the market capitalisation of Entrada Therapeutics Inc (TRDA)?
The market capitalisation of Entrada Therapeutics Inc is $274M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Entrada Therapeutics Inc (TRDA)?
The price-to-sales ratio of Entrada Therapeutics Inc is 56.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Entrada Therapeutics Inc (TRDA)?
Earnings per share at Entrada Therapeutics Inc are $−3.96. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Entrada Therapeutics Inc (TRDA)?
The return on equity (ROE) of Entrada Therapeutics Inc is −54.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Entrada Therapeutics Inc (TRDA)?
On an EBIT basis the return on assets of Entrada Therapeutics Inc is −17.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Entrada Therapeutics Inc (TRDA)?
The operating margin of Entrada Therapeutics Inc is −5,007% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Entrada Therapeutics Inc (TRDA)?
Revenue at Entrada Therapeutics Inc is growing −53.9% versus a year earlier (3y avg +0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Entrada Therapeutics Inc (TRDA) generate?
The free cash flow of Entrada Therapeutics Inc is −$130M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Entrada Therapeutics Inc (TRDA) hold?
Entrada Therapeutics Inc holds more cash than debt, $39.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Entrada Therapeutics Inc in the live analysis

One click puts Entrada Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.